| Literature DB >> 31788417 |
Alexander Klein1, Felix Tauscher1, Christof Birkenmaier2, Andrea Baur-Melnyk3, Thomas Knösel4, Volkmar Jansson2, Hans Roland Dürr1.
Abstract
INTRODUCTION: Clear cell chondrosarcoma (CCC) is a rare subtype of chondrosarcoma and it is commonly considered a low-grade tumor and less aggressive than atypical cartilaginous tumor (grade 1 central chondrosarcoma). However, the experience even of musculoskeletal tumor centres with this rare entity is limited. The aim of this study is to analyse our own treatment results and those of the literature regarding the therapy and outcome of this lesion.Entities:
Keywords: AWD, alive with disease; CCC, clear cell chondrosarcoma; CS, chondrosarcoma; CT, computed tomography; Clear Cell Chondrosarcoma; DOD, dead of disease; LR, local recurrence; LRFS, local recurrence free survival; MD, metastatic disease; MRI, magnetic resonance imaging; Margin status; N/A, not available; NED, no evidence of disease; OS, overall survival; Prognostic factors; Recurrence; Surgery
Year: 2019 PMID: 31788417 PMCID: PMC6879987 DOI: 10.1016/j.jbo.2019.100267
Source DB: PubMed Journal: J Bone Oncol ISSN: 2212-1366 Impact factor: 4.072
Fig. 1a,b: X-rays of a 29 year-old male patient (patient #2) with a osteolytic lesion of the epiphysis and metaphysis of the proximal humerus. The lesion has sharp rims and shows a slight sclerosis of the borders, an unspecific finding, but typical of CCC; c-e: the MRI clearly shows the exact location and extent of the tumor but is unspecific. Coronal STIR (e) shows hyperintensity of the lesion. T1 –w TSE sequence pre- and post-contrast (c, d) show a homogeneous enhancement within the tumor. There are no rings or arcs patterns of enhancement which would be typical for chondroid tumors.
Fig. 2Clear cell chondrosarcoma (patient #2): a: Sheets of clear cells with areas of mature hyaline cartilage (40x magnification); b: atypical clear cells with permeative growth (10x magnification).
data of evaluated cases (Abbreviations: N/A – not available; Grading: Low - low-grade; High - high-grade; FU: NED - No Evidence of Disease; AWD – alive with disease; DOD – dead of disease).
| Author | Year | Patients (n) | Grading | Follow-up (FU) | Follow-up (months) | Margins | Local recurrence | Metastatic disease (MD) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LR (n;%) | Time to local recurrence (months) | Mets (n;%) | Time to MD | Location | |||||||
| Unni et al. | 1976 | 16 | 2 × × N/A | 1 × N/A | 4–252 | 1 × N/A | 4; 25% | 3–60 (median 24) | 6; 38% | 71–228 (median 81) | 5 × lung |
| 8 × Low | 10 × NED | 8 × R0 | 2 × bone | ||||||||
| 6 × High | 1 × AWD. | (median 63) | 7 × R1/2 | ||||||||
| 4 × DOD | |||||||||||
| Le Charpentier et al. | 1979 | 5 | 4 × Low | 4 × NED | 24–156 (median 30) | 4 × R0 | 1; 20% | 36 | 0 | – | – |
| 1 × High | 1 × DOD | 1 × R1 | |||||||||
| Salzer-Kuntschik et al. | 1981 | 1 | 1 × Low | NED | 69 | R1 | 1 | 46 | 0 | – | – |
| Bjornsson et al. | 1985 | 47 | N/A | 9 × N/A | 2–323 (median 72) | 5 × N/A | 16; 34% | 56 | 7; 15% | 42–84 (median 48) | 5 × lung |
| 22 × NED | 23 × R0 | 3 × bone | |||||||||
| 8 × AWD | 19 × R1 | ||||||||||
| 8 × DOD | |||||||||||
| Komiya et al. | 1986 | 1 | 1 × Low | DOD | 54 | R2 | 0 | – | 1 | 48 | Bones / lung |
| Ohno et al. | 1986 | 1 | 1 × Low | NED | 39 | R0 | 0 | – | 0 | – | – |
| Present et al. | 1988 | 1 | 1 × Low | NED | 18 | R0 | 0 | – | 0 | – | – |
| Chan et al. | 1989 | 1 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Lee at al. | 1989 | 1 | 1 × Low | NED | 70 | R1 | 1 | 64 | 0 | – | – |
| Welkerling et al. | 1990 | 1 | 1 × Low | NED | 22 | R0 | 0 | – | 0 | – | – |
| Sreekantaiah et al. | 1991 | 1 | 1 × Low | NED | 11 | R0 | 0 | – | 0 | – | – |
| Bosse et al. | 1991 | 3 | 3 × Low | N/A | N/A | N/A | – | – | – | – | – |
| Singh et al. | 1991 | 2 | N/A | NED | 5; 7 | – | 0 | – | o | – | – |
| Bagley et al. | 1993 | 2 | 2 × LG | 1 × NED | 6; 280 | 2 × R0 | 0 | – | 1; 50% | 276 | Bones |
| 1 × AWD. | |||||||||||
| Ron et al. | 1995 | 1 | 1 × LG | AWD | 13 | R0 | 1 | 5 | 1 | 12 | Lung |
| Aigner et al. | 1995 | 2 | 2 × LG | N/A | N/A | N/A | 0 | – | 0 | – | – |
| Brien et al. | 1996 | 1 | 1 × LG | NED | 24 | N/A | 0 | – | 0 | – | – |
| Pinieux et al. | 1998 | 1 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Masui et al. | 1999 | 4 | 4 × LG | N/A | N/A | N/A | – | – | – | – | – |
| Ishida et al. | 1999 | 1 | 1 × LG | NED | 11 | R0 | 0 | – | 0 | – | – |
| Nathan et al. | 1999 | 1 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Ayoub at al. | 1999 | 6 | N/A | 4 × NED | 12–240 (median 51) | 3 × R0 | 3; 50% | 34–228 (mean 60) | 1; 17% | 66 | Lung |
| 1 × AWD | 3 × R1/2 | ||||||||||
| 1 × DOD | |||||||||||
| Hartwright et al. | 2000 | 1 | 1 × LG | NED | 252 | R0 | 1 | 228 | 0 | – | – |
| Kalil et al. | 2000 | 3 | 3 × HG | 3 × DOD | 36–98 (median 72) | 2 × R0 | 2; 67% | 8; 72 | 3; 100% | 15–72 (median 66) | 3 × lung |
| 1 × R1 | 2 × bone | ||||||||||
| Engels et al. | 2000 | 16 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Cannon et al. | 2002 | 1 | N/A | NED | 24 | R0 | 0 | – | 0 | – | – |
| Memis et al. | 2002 | 2 | N/A | N/A | N/A | 2 × R0 | 0 | – | 0 | – | – |
| Itälä et al. | 2005 | 16 | N/A | 11 × NED | 88–233 (median 161) | 10 × R0 | 3; 19% | 2–22 (median 20) | 3; 16% | 48–196 (median 84) | 1 × lung |
| 4 × AWD | 6 × R1 | 2 × bone | |||||||||
| 1 × DOD | |||||||||||
| Kawano et al. | 2005 | 1 | 1 × HG | NED | 50 | R0 | 0 | – | 1 | 48 | Bone |
| Srikanth et al. | 2006 | 1 | 1 × HG | DOD | N/A | R0 | 0 | – | 1 | x | Lung |
| Simsek et al. | 2005 | 1 | 1 × LG | NED | 72 | R2 | 1 | 36 | 0 | – | – |
| Nishio et al. | 2005 | 4 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Tessitore et al. | 2006 | 1 | N/A | NED | 12 | R1 | 0 | – | 0 | – | – |
| Donati et al. | 2008 | 18 | N/A | 15 × NED | 60–445 (median 240) | 17 × R0 | 5; 28% | 6–288 (median 56) | 2; 11% | 12; 64 (mean 38) | Bone |
| 3 × AWD | 1 × R1 | ||||||||||
| Kuroda et al. | 2009 | 1 | N/A | NED | 6 | R0 | 0 | – | 0 | – | – |
| Hsu et al. | 2011 | 1 | N/A | NED | 24 | R0 | 0 | – | 0 | – | – |
| Sisu et al. | 2011 | 1 | 1 × HG | N/A | N/A | N/A | – | – | – | – | – |
| Paidakakos et al. | 2012 | 1 | 1 × LG | NED | 12 | R0 | 0 | – | 0 | – | – |
| Ryu et al. | 2012 | 1 | 1 × LG | NED | 42 | R0 | 0 | – | 0 | – | – |
| Elojeimi et al. | 2013 | 1 | 1 × HG | 1 × AWD | 36 | R0 | 0 | – | 1 | 12 | Bone |
| Matsuura et al. | 2013 | 5 | N/A | N/A | N/A | N/A | – | – | – | – | – |
| Manfrini et al. | 2014 | 1 | N/A | NED | 240 | R0 | 0 | – | 0 | – | – |
| Jiang et al. | 2014 | 5 | N/A | 1 × NED | 14–242 (median 120) | 3 × R0 | 3; 60% | 12–96 (median 30) | 3; 60% | 110–240 (median 120) | Bone |
| 3 × AWD | 2 × R1 | ||||||||||
| 1 × DOD | |||||||||||
| Laitinen et al. | 2014 | 1 | 1 × LG | AWD | 378 | R1 | 1 | 348 | 1 | 348 | Lung |
| Tay et al. | 2014 | 1 | N/A | NED | N/A | R0 | 0 | – | 0 | – | – |
| Nagmani et al. | 2015 | 1 | N/A | AWD | 18 | R0 | 0 | – | 1 | 18 | Lung |
| Liska et al. | 2015 | 1 | 1 × LG | NED | 106 | R1 | 1 | 84 | 0 | – | – |
| Moura et al. | 2016 | 1 | N/A | NED | 204 | R1 | 1 | 192 | 0 | – | – |
| Own cases | 7 | 7 × LG | 6 × NED | 22–160 (mean 55) | 7 × R0 | 1; 14% | 71 | 1; 14% | 9 | Lung | |
| 1 × DOD | |||||||||||
| Total | 194 | 55 × Low | 96 × NED | 2–445 (Median 83) | 99 × R0 | 46; 32,2% | 2–348 (mean 64, median 34) | 34; 23,8% | 9–348 (mean 92, median 71) | 15 × Lung | |
| 23 × AWD | 48 × R1/2 | 13 × bone | |||||||||
| 6 × High | 24 × DOD | 6 × multiple | |||||||||
Fig 3Location of tumor in all patients.
Fig 4Overall survival (a) and disease free survival (b) in 143 patients with CCC.
Fig. 5a: overall (p = 0.047) and b: local recurrence free survival (LRFS) (p = <0,001) of patients depending on resection margin.
Fig 6Overall survival depending on local recurrence (LR) (p = 0,006).
Fig. 7Metastasis-free survival depends on occurring of local recurrence (LR) (p = 0,034).
Cox proportional-hazards regression for overall survival in relation to grading, metastatic disease, margin status and local recurrence.
| Varriables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | Hazard ratio (95% CI) | |||
| Grading | 1,44–142,56 | 0,136 - 2572 | 0,484 | |
| Metastatic disease | 65–110 | 0,002 - 0,343 | ||
| Margin status | 69–410 | 1138 - 112,152 | ||
| Local recurrence | 112–357 | 0,020 - 1309 | 0,088 | |